Amicus Therapeutics Is Set To Revolutionize The Treatment Of Genetic Disorders

In just 10 years, Amicus Therapeutics has risen to the forefront of the biotechnology industry with a fresh approach to the treatment of genetic disorders and illnesses. The company’s own website boasts a wide range of drug therapies designed to treat a spectrum of rare genetic disorders.
Among the company’s greatest achievements, Amicus Therapeutics has recently unveiled a treatment for Fabry disease, a rare genetic disorder named for Johannes Fabry. The new course of treatments will be also be used to treat Pompe disease and other Lysosomal Storage Disorders through enzyme replacement therapy.
Developing a treatment plan for Lysosomal Storage Disorders is a tremendous advance, but it’s also the kind of thing this growing biotechnology company hopes to do regularly. Since its 2007 inception, Amicus Therapeutics has pledged to deliver the best possible treatments for people living with genetic diseases.
To maintain a vigilant focus on that directive, Amicus Therapeutics keeps a close eye on the community of families affected by rare and orphan genetic illnesses, providing them with support and offering new treatments, as they become available. In that vain, the biotechnology company is keeping an ear to the ground, looking for innovative ways to adapt new technologies and to outperform their own advances.
While Amicus Therapeutics’ own mission statement reveals a thirst for rapid advancement, the company is only limited by a desire for safety in their research and testing phases.
A code of conduct guides Amicus Therapeutics in all areas, from research and development to corporate decision making policies. A message from Patrik Florencio, Amicus Chief Compliance and Risk Officer, emphasizes that care for ethical actions on behalf of the company, ensuring that a concern for their patients won’t forsake greater concerns for the environments in which Amicus Therapeutics operates.
Speaking of their patients, Amicus Therapeutics takes their devotion to their patients into account, when considering new treatments. In searching for new treatments, Amicus collects research that will lead them toward more effective treatments for current and future patients. Incorporating patient input into developing each new therapy, Amicus Therapeutics remains at the forefront of the biotechnology industry .
Visit Amicus Therapeutics on Twitter or see job opportunities at Indeed



End Citizens United is a Political Action Committee (PAC) established on March 1, 2015. The group’s main aim is to reverse Citizens United which is a Supreme Court’s decision that unleashed lots of dark money into politics in 2010. The group intends to bring about reforms in the country’s campaign finance system by raising the issue of money in politics as a national priority, electing pro-reform candidates and to demonstrate political power on the issue of money in politics by using grassroots membership. The PAC is determined to end the unlimited and dark money in politics.

End Citizens United receives funding from its grassroots supporters and it embodies the immense force with which the grassroots are fighting against billionaires who buy the country’s elections. The PAC had received more than 325,000 signatures for their petition from supporters by August 2015. By this time, they had also raised over $2 million with an aim of raising the figure to $30 million before the campaign period. Serving as an example of political transparency and openness, End Citizens United has made their Federal Elections Commission (FEC) filings available to the public. They have vowed to continue doing so for the purposes of promoting democracy in the country.

The group’s intention is to channel millions of dollars into financially supporting pro-reform candidates vying for both House and Senate positions in the 2016 elections. They have decided to support Democrats in the 2016 elections, both for House and Senate positions. Such support will be in the form of paying for financial ads, direct mailers and polling. They named eleven Democratic candidates they endorse to run for various positions in the elections. Moreover, they have entered into partnership with the “Ready for Hillary” movement. Their decision is owed to the fact that Democrats have been on the forefront when it comes to fighting against Citizens United. A Democrats leadership is their only hope they have for reform since Republicans in the congress have continued to hinder the reversal of the Citizens United decision. It is also Democrats who have majorly suffered the effects of the dark-money groups in politics. Read more news about the group on MSNBC.

Campaign finance experts are, however, sceptical about the success of the PAC’s efforts. For a constitutional amendment to be implemented, it has to win a two-thirds consent of the House and the Senate as well as a three-fourths of all the states. This may be a very tough battle for the PAC to win not forgetting that America has not passed any constitutional amendment since 1992. Failure to win a constitutional amendment does not, in any case, render the PAC useless since it could continue serving as a public awareness tool. Such might be so powerful to an extent that it keeps the Supreme Court and the political fraternity in check and ensure no worse decisions are made. Follow the group on